to sunitinib malate in treating patients with previously untreated locally advanced or
metastatic kidney cancer. Cabozantinib-s-malate and sunitinib malate may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known
whether cabozantinib-s-malate or sunitinib malate is more effective in treating patients
with kidney cancer.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: firstname.lastname@example.org
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.